Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Genaera Corp

No earlier versions found for this Subject.

Return to Genaera Corp

Genaera Corporation is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. The Company's research and development efforts are focused on anti-angiogenesis and respiratory diseases. Squalamine is a naturally occurring water-soluble small molecule and the Company's lead anti-angiogenic development candidate. The Company's development efforts for this anti-angiogenic molecule are focused on serious diseases, including age-related macular degeneration and cancer. It also maintains a respiratory product development program designed to discover and develop treatment alternatives for respiratory diseases. Through genomics research, Genaera has concentrated its efforts on determining the manner in which genes specifically impact respiratory disease. Its first genomics-based program is focused on the development of a blocking antibody to interleukin-9 to treat a root cause of asthma.